Preventing Acute Kidney Disease

RenalGuard focused on the cardiac and vascular markets.

PLC's lead product, RenalGuard®, has been developed to rapidly remove contrast dyes that may be toxic to the kidney in at-risk patients undergoing certain cardiac and vascular imaging procedures.  This damage can lead to Contrast-Induced Nephropathy (CIN), a form of acute kidney injury.

Renal Guard More Info

RenalGuard®

A Therapeutic Approach to Reducing Contrast-Induced Nephropathy (CIN)

Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing Contrast-Induced Nephropathy (CIN)

Renal Guard More Info

Contrast-Induced Nephropathy (CIN)

Contrast-Induced Nephropathy (CIN) is a form of acute kidney injury resulting from toxic contrast agents that occurs in 10% to 20% of at-risk patients.

Renal Guard More Info

PLC Medical Systems

PLC Medical Systems, Inc., the operating subsidiary of PLC Systems Inc., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's lead product, RenalGuard®, is designed to rapidly remove contrast dyes that are known to be toxic to the kidneys.  Contrast dyes are used in many cardiovascular diagnostic and interventional imaging procedures to facilitate the capture and display of x-ray images.  Approximately 10% to 20% of patients that undergo these procedures are at-risk of developing Contrast-Induced Nephropathy (CIN), a form of acute kidney injury resulting from toxic contrast dye. RenalGuard is CE-marked and is being sold in Europe and certain countries around the world via a network of distributors. Two investigator-sponsored studies in Europe have demonstrated RenalGuard's effectiveness at preventing CIN. The CIN-RG RenalGuard pivotal study is underway in the U.S. to support a planned Premarket Approval filing with the U.S. Food and Drug Administration.

Caution - INVESTIGATIONAL DEVICE, LIMITED BY UNITED STATES LAW TO INVESTIGATIONAL USE.

RenalGuard

RenalGuard Therapy®

PLC Systems’ RenalGuard Therapy® is designed to reduce the toxic effects that contrast media can have on the kidneys for patients undergoing imaging procedures. This therapy is based on the theory that creating and maintaining a high urine output allows the body to rapidly eliminate contrast, reducing its toxic effects.

Learn more